Did not become law. It stopped in the Senate on March 11, 2020. The 2020 session has ended.
2020 Regular Session
Senate Bill 138
AN ACT REQUIRING MANUFACTURERS OF BRAND NAME PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS.
What it does
The synopsis the General Assembly published with the bill.
To promote competition in the prescription drug market by allowing developers of generic drugs and biosimilar products to obtain reference samples.
Sponsors
Who carried the bill in each chamber, and who signed on. Each name leads to the member's page.
Its course
February 19 to March 11, 2020, on one scale. In the top row each mark is a day something happened; taller marks are busier days.
Each committee stop sits inside its chamber.
Every action4 actions on 4 days
In the SenateFeb 19 to Mar 11 · stopped21 days
General Law CommitteeFeb 19 to Mar 1020 days
Text
Each version as the General Assembly printed it.
l9n doesn't hold this bill's text yet.
What happened
In l9n's words, one line for each step. Every action as the General Assembly published it is below.
In the Senate Feb 19 – Mar 10
- Feb 19Introduced and sent to General Law Committee
- Feb 21Heard in General Law Committee
- Mar 10General Law Committee recommended it
All 4 actions, as published
- Feb 19REF. TO JOINT COMM. ONBoth houses
- Feb 21PUBLIC HEARINGBoth houses
- Mar 10Joint FavorableBoth houses
- Mar 11FILED WITH LCOBoth houses